Advanced BioHealing hopes for $200 million in IPO

Advanced BioHealing, a regenerative medicine company developing and commercialising living cell therapies, has filed an initial public offering with US regulators, hoping to raise $186-213 million before deductions part of which will be spent on a second manufacturing facility and part of which may be used for in-licensing or acquisitions. The issue puts for 13.35 million shares on the table with the company hoping for a share price between $14 and $16 each.

The company, based in Westport, Connecticut, markets the tissue-engineered substitute Dermagraft, which assists in restoring damaged tissue and is currently...